May 12, 2021
Fuji Yakuhin said on May 10 that it has entered into a license agreement with US-based biopharma Fortress Biotech for the exclusive rights to develop and market the Japanese company’s gout and hyperuricemia treatment dotinurad in North America and Europe...read more